Study of a new eye drop for advanced glaucoma
Part of Brain & nervous system, Eyes & vision clinical trials.
This trial tests an investigational eye drop called ASP2767 to see if it is safe and can help slow or prevent further vision loss in people with advanced glaucoma-related optic nerve damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have open-angle glaucoma confirmed by a doctor, with moderate to severe vision loss in one eye.
- Your eye pressure is controlled (21 mmHg or lower, and no surgery in the study eye may be okay.
- You have not had certain eye surgeries or certain eye surgeries more than 12 weeks ago, or 3 months ago, or 3 months after a recent eye surgery within 12 weeks ago, and have not had a recent surgery within 12 weeks.
- You are not using certain medications that could affect vision (like Plaquenil, amiodarone, ethambutol, etc.) currently.
- You have no other eye diseases (like retinal degeneration or uveitis) that could affect vision.
- You have no serious medical conditions like uncontrolled diabetes (HbA1c > 7%), uncontrolled high blood pressure, or history of certain autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a common class of glaucoma eye drops (called prostaglandin analogues) can protect the nerve cells in the back of the eye. It may help people with certain types of glaucoma who have been stable on one type of eye drop for at least 3 years.
This study tests new ways to diagnose glaucoma (and sometimes related eye conditions) using eye exams and measurements. It may help improve how doctors detect glaucoma earlier and more accurately.
This study tests an eye drop (G01) for people with primary open-angle glaucoma that is getting worse despite current treatments. It aims to see if G01 can safely slow down or stop the progression of glaucoma.
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
This study tests a new eye drop against an existing one to see which better lowers eye pressure in people with open-angle glaucoma or ocular hypertension. You may be able to join if you have high eye pressure in both eyes that needs treatment and you are at least 18 years old.
This trial tests an investigational drug called REGN22530 for people with mild to moderate primary open-angle glaucoma or ocular hypertension (high eye pressure). The goal is to see if it can safely lower eye pressure and protect vision.
Hear when a new Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.